Description
What Is Bronchogen Peptide?
Bronchogen peptide is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Leu (AEDL), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Bronchogen targets bronchial and pulmonary tissue, functioning as a lung bioregulator that tunes gene expression in bronchial epithelial cells, alveolar type II pneumocytes, and supporting respiratory structures. It belongs to the Khavinson bioregulator peptides class — short control peptides that show tissue-specific gene expression tuning at natural levels — and has been studied in lab models of respiratory aging, chronic bronchial disease, pulmonary tissue repair, and age-related lung functional decline.
The respiratory system faces a unique aging challenge: continuous exposure to environmental oxidants, particulate matter, and pathogens creates cumulative tissue damage that compounds epigenetic aging of bronchial and alveolar cells. Unlike the liver or skin, pulmonary tissue has limited regrowth capacity, making the preservation and restoration of existing respiratory cell function key to keeping lung health during aging. Bronchogen addresses this challenge at the transcriptional level, tuning the gene expression programs that govern bronchial epithelial integrity, mucociliary clearance, and alveolar gas exchange. PrymaLab Bronchogen 20mg is manufactured to high purity standards and supplied exclusively for qualified lab research.
Bronchogen 20mg: Key Specifications
How Does Bronchogen Peptide Work?
Epigenetic Gene Expression Modulation in Pulmonary Tissue
Bronchogen operates through the peptide-DNA interaction mechanism described by Professor Khavinson’s research group, wherein the AEDL sequence selectively binds specific DNA motifs within gene promoter regions of respiratory cells and tunes chromatin conformation. In bronchial and alveolar tissue, bronchogen influences the expression of genes governing epithelial barrier function, mucin production, surfactant synthesis, and swelling response control. This epigenetic mechanism operates at physiologically relevant levels, distinguishing bioregulator peptides from pharmacological bronchodilators or anti-swelling agents.
Bronchial Epithelial Integrity and Mucociliary Function
The bronchial epithelium serves as the main barrier between the external environment and pulmonary tissue. Age-related decline in epithelial tight junction protein expression, ciliary beat frequency, and mucin makeup compromises this barrier, increasing susceptibility to infection and environmental damage. Bronchogen research has showed tuning of genes governing epithelial cell-cell adhesion, ciliary protein expression, and mucin glycoprotein production, positioning it as a research tool for studying the maintenance of bronchial barrier function during aging.
Alveolar Function and Gas Exchange
At the alveolar level, bronchogen targets type II pneumocytes — the cells responsible for surfactant production and alveolar epithelial renewal. Age-related decline in surfactant synthesis impairs gas exchange efficiency and reduces alveolar compliance. Lab research has shown that bronchogen tunes surfactant protein gene expression and supports type II pneumocyte function, addressing the alveolar component of respiratory aging that directly impacts oxygen transfer capacity.
Bronchogen Peptide Benefits Reported in Preclinical Research
Published studies on bronchogen peptide benefits report multiple respiratory-specific effects relevant to lung aging and pulmonary research. All findings described below are from lab animal and cell culture models.
Restoration of Bronchial Epithelial Function
The most consistently reported bronchogen peptide benefit is the restoration of bronchial epithelial integrity in aged and damaged respiratory tissue models. Studies show improved tight junction protein expression, normalized mucociliary clearance rates, and enhanced epithelial cell renewal in aged bronchial tissue exposed to bronchogen. These findings suggest that epigenetic tuning can counteract the progressive breakdown of the bronchial barrier that characterizes respiratory aging.
Anti-Inflammatory Effects in Respiratory Tissue
Chronic low-grade airway swelling accelerates pulmonary aging and adds to age-related respiratory diseases. Among the documented bronchogen benefits, suppression of pro-swelling gene expression in bronchial tissue (including reduced NF-κB pathway start, decreased IL-8 and TNF-α expression) and enhanced anti-swelling mediator production have been consistently reported. These anti-swelling effects distinguish bronchogen from conventional bronchodilators that address symptoms rather than underlying swelling gene programs.
Surfactant Production and Alveolar Maintenance
Enough surfactant production is essential for alveolar shelf life and efficient gas exchange. Bronchogen research reports enhanced surfactant protein gene expression (SP-A, SP-B, SP-D) and improved alveolar type II pneumocyte function in aged pulmonary tissue models. These findings have specific relevance to research on age-related declines in respiratory capacity and oxygen saturation.
Pulmonary Fibrosis Modulation
Progressive pulmonary fibrosis reduces lung compliance and impairs respiratory function during aging. Lab bronchogen studies report tuning of fibrotic gene expression in lung tissue, including reduced collagen deposition and decreased transforming growth factor beta signaling in respiratory interstitium. These anti-fibrotic effects position bronchogen as a research compound for studying the reversibility of age-related pulmonary stiffening.
Respiratory Anti-Aging in Longitudinal Models
Long-term animal studies by the Khavinson group have reported that bronchogen use is linked with preserved lung function parameters, kept respiratory capacity, and reduced histological signs of pulmonary aging in chronically treated cohorts compared to controls. These respiratory anti-aging findings support the broader bioregulatory hypothesis that tissue-specific gene expression tuning can slow organ-specific aging trajectories.
Bronchogen Dosage in Research Applications
Published research provides context for bronchogen dosage parameters across experimental paradigms. The following represents reported dosage ranges from lab literature and is intended solely to inform research protocol design.
| Research Use |
Reported Dosage Range |
Protocol Context |
| Cell Culture (Bronchial Epithelial) |
10–100 nM |
Gene expression and barrier function studies |
| Respiratory Aging Models |
1–10 µg/kg |
Chronic use in aged rodent pulmonary studies |
| Airway Swelling Models |
5–20 µg/kg |
Anti-swelling protocols in chronic bronchial paradigms |
| Combined Respiratory Protocols |
1–10 µg/kg each |
Multi-peptide regimens (e.g., bronchogen + chonluten) |
Important: These are reported research dosages from published lab literature. Best dosing depends on experimental design, animal model, route of use, and research objectives. This product is not intended for treatment use.
Bronchogen vs. Chonluten: Respiratory Bioregulator Comparison
Researchers studying respiratory aging often compare bronchogen and chonluten because both target the respiratory system within the Khavinson bioregulator framework. Grasp their distinct tissue targets and mechanisms is essential for selecting the appropriate respiratory bioregulator peptide for specific research uses.
| Feature |
Bronchogen |
Chonluten |
| Classification |
Lung bioregulator (bronchial/pulmonary tissue) |
Respiratory bioregulator (bronchopulmonary mucosa) |
| Sequence |
Ala-Glu-Asp-Leu (AEDL) |
Glu-Asp-Gly (EDG) |
| Main Target |
Bronchial epithelium, alveolar pneumocytes |
Respiratory mucosal epithelium, submucosal glands |
| Mechanism Focus |
Epithelial barrier, surfactant production, gas exchange |
Mucosal immunity, secretory function, mucosal renewal |
| Anti-swelling Profile |
NF-κB suppression, IL-8 and TNF-α reduction |
Mucosal immune tuning, secretory IgA support |
| Key Research Use |
Bronchial integrity, alveolar function, pulmonary fibrosis |
Mucosal barrier defense, respiratory mucosal aging |
| Best For |
Structural lung aging: epithelium, alveoli, fibrosis |
Mucosal respiratory aging: immunity, secretion, defense |
| Combined Use |
Paired: structural + mucosal respiratory support |
Paired: mucosal + structural respiratory support |
The bronchogen-chonluten mix represents the most full respiratory bioregulator research approach in the Khavinson system, with bronchogen addressing the structural and functional components of the lung (epithelial barrier, alveolar gas exchange, surfactant) and chonluten targeting the mucosal immune defense layer. Researchers studying systemic respiratory aging may benefit from protocols incorporating both peptides for complete airway coverage.
How to Store and Handle PrymaLab Bronchogen 20mg
- Store freeze-dried at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
- Allow vial to reach room heat before opening to prevent condensation.
- Reconstitute with appropriate sterile solvent. Add slowly along vial wall.
- Use mixed solution within 2–4 weeks. Refrigerate at 2–8°C.
- Avoid repeated freeze-thaw cycles. Aliquot into single-use portions.
- Retain the Certificate of Test for lot traceability.
Why Choose PrymaLab Bronchogen 20mg?
PrymaLab supplies Bronchogen 20mg as a high-purity research-grade lung bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Test. Independent third-party testing ensures unbiased quality check and full traceability for GLP-compliant pulmonary and respiratory research.
Frequently Asked Questions About Bronchogen Peptide
What is bronchogen peptide and what does it target?
Bronchogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu, AEDL) developed by Professor Khavinson targeting bronchial and pulmonary tissue. It tunes gene expression in bronchial epithelial cells, alveolar type II pneumocytes, and supporting respiratory structures. Research uses include respiratory aging, chronic bronchial disease, pulmonary fibrosis, and lung function preservation in lab models.
What are the reported bronchogen peptide benefits in research?
Published lab research reports bronchogen peptide benefits including restored bronchial epithelial barrier function (improved tight junctions and mucociliary clearance), anti-swelling gene tuning in airway tissue, enhanced surfactant protein expression in alveolar cells, reduced pulmonary fibrotic gene expression, and preserved lung function parameters in longitudinal aging models. All benefits are from lab research.
How does bronchogen differ from chonluten?
Both bronchogen (AEDL) and chonluten (EDG) target the respiratory system, but they address different tissue layers. Bronchogen focuses on structural lung components (bronchial epithelium, alveolar pneumocytes, surfactant production) while chonluten targets the mucosal defense layer (mucosal immunity, secretory function, mucosal renewal). Combined protocols may provide full respiratory bioregulation.
What is the recommended bronchogen dosage for research?
Published bronchogen peptide dosage ranges include 10–100 nM for cell culture studies and 1–10 µg/kg for in vivo respiratory aging models. Dosing depends on experimental design, model system, and research objectives. This product is for lab research only and is not intended for treatment dosing.
How should bronchogen be stored?
Store freeze-dried bronchogen at −20°C, desiccated and protected from light, for 24+ months shelf life. After mixing, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.
Research Disclaimer
For Research Use Only. PrymaLab Bronchogen 20mg is intended exclusively for qualified lab research use. This product is not intended for human consumption, treatment use, veterinary treatment, or any use outside controlled research environments. Bronchogen has not been approved by the FDA or any equivalent control authority for treatment use. All research uses described are from published lab and gerontological literature. Researchers are responsible for control compliance.
14 reviews for Bronchogen Peptide 20mg